Third Party Manufacturer Lapses – Marketers Will Need To Share Onus In India
Executive Summary
Drug marketers who don’t own-manufacture products in India may no longer be able to shrug off responsibility in the event of quality lapses at their third-party manufacturers.
You may also be interested in...
Lapses In Drug Quality - Marketers Will Also Be Accountable In India
New proposed rules in India require the marketer of a drug to share responsibility for its quality along with the manufacturer.
Interview: Eisai India Unit’s Pivotal Role As Japan Genericizes
Eisai India chief Dr. Sanjit Singh Lamba outlines the competitive edge that the Japanese group’s Indian site offers under the deal with Nichi-Iko; the site has also never “depended” on active pharmaceutical ingredients from China. In a wide-ranging interview with Scrip, Lamba also discusses recent quality compliance initiatives in India.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.